Acromegaly Update podcast

Acromegaly Update — Monday October 26, 2026

0:00
5:00
Rewind 15 seconds
Fast Forward 15 seconds
A thin top-tier week for acromegaly (one Pituitary paper plus a handful of solid next-tier studies, including a 2026 pipeline review), while rare disease news was dominated by positive Phase 3 readouts from Disc Medicine and Roivant, a second FDA look at Biohaven's ataxia drug, and early Huntington's data from Alnylam.

More episodes from "Acromegaly Update"